SMMT Latest Headlines

3 things to look out for on Friday

at seekingalpha.com (Thu, 12-Nov 4:35 PM)

Wall Street Analysts Are Bullish on Top Healthcare Picks

at www.tipranks.com (Wed, 11-Nov 7:20 AM)

Summit Therapeutics: Hold Maintained as Binary HARMONi-3 Risk Tempers Outlook; $11.90 Price Target Unchanged

at www.tipranks.com (Tue, 10-Nov 7:26 AM)

Summit Therapeutics spotlights $2.0B AstraZeneca equity investment as ivonescimab program expands into bladder and kidney cancers

Market Chameleon (Thu, 5-Nov 9:01 AM)

SMMT teams with Lunit to apply AI pathology to tumor microenvironment analysis for ivonescimab programs

Market Chameleon (Mon, 26-Oct 11:26 AM)

Summit Therapeutics joins ECOG-ACRIN for a registration-enabling ivonescimab study in first-line biliary tract cancer

Market Chameleon (Wed, 21-Oct 9:01 AM)

Summit Therapeutics Opens a 100-Patient Phase II Kidney Cancer Study Testing Three Ivonescimab-Based Regimens Against a Standard Comparator

Market Chameleon (Mon, 19-Oct 11:43 AM)

Summit Therapeutics Opens a 100-Patient Phase II Kidney Cancer Trial Testing Ivonescimab Against Standard Immunotherapy

Market Chameleon (Mon, 19-Oct 9:13 AM)

SMMT teams with AstraZeneca and Daiichi Sankyo to test ivonescimab plus Datroway, starting in Phase III TNBC

Market Chameleon (Fri, 2-Oct 7:35 AM)

AstraZeneca’s $2 Billion Preferred-Share Deal Puts an $18.36 Conversion Price on Summit Therapeutics (SMMT)

Market Chameleon (Tue, 29-Sep 10:29 AM)

AstraZeneca’s $2 Billion Convertible Preferred Deal Puts an $18.36 Per-Share Marker on Summit Therapeutics (SMMT)

Market Chameleon (Tue, 29-Sep 8:28 AM)

Ivonescimab Shows Significant Survival Benefit Over Durvalumab in Advanced Biliary Tract Cancer—What This Means for Summit Therapeutics’ Pipeline

Market Chameleon (Wed, 26-Aug 11:44 AM)

Ivonescimab Plus Chemotherapy Extends Progression-Free Survival in EGFR-Mutated NSCLC: Phase III HARMONi Study Results Published

Market Chameleon (Tue, 25-Aug 8:13 AM)